• Medical Cannabis Conference, all presentations

    Original Date: July 29-30, 2017

    This discounted package includes all of the individual presentations from the conference.

    12.0 CEUs (including 9.0 pharmacy and 3.0 general) approved by OBNM
  • Cannabis in the Therapeutic Order

    Presenter: Paul Bergner
    Original Date: July 29, 2017

    Cannabis is now legal for some medical purposes in the majority of states in the U.S. and millions of patients now take it on a daily basis for various health problems. The Therapeutic Order, from naturopathic practice, describes a clinical strategy which relies first on supporting the normal determinants of health and life, such as diet, activity, rest, and on quality or air, then on stimulating or supporting normal physiological processes with natural methods, or correcting physical lesions with bodywork or manipulation. Such methods may be curative, and may remove the cause of a condition. Lower on the therapeutic order is intervention with strong pharmacological agents; lower because these are never curative, and they produce side effects or distortions of normal physiological function.

    The use of medical Cannabis may be necessary or desirable on a short or long term for some patients, but it is never curative for the conditions it is used to treat, and chronic daily use is associated with acute and chronic side effects, including increased tolerance, decreased effectiveness over time, and a withdrawal syndrome in habituated chronic users. Accumulating evidence indicates that subtle deficits in cognition and executive function are nearly universal in chronic users. Other side effects, such as the Cannabis emesis syndrome, or disruption of male or female reproductive function, are common in daily users yet are usually not recognized by practitioners as side effects. This presentation reviews some of the approved uses of medical Cannabis, with suggestions for alternative or supporting approaches. The presentation is based on a science review and results and statistics from a case series of 40 heavy daily Cannabis users.

    Pharmaceuticals and pharmacology of botanicals covered include Cannabis, and Vitex agnus-castus.

    2.0 general CEUs approved by OBNM
  • Practical Use of Cannabinoids in Clinical Practice

    Presenter: Chris Meletis, ND, Brian Martin, ND, & Joost Luecker, PhD, MSc
    Original Date: July 29, 2017

    In this presentation a panel of experts explores and review clinical rationale for use of CBD. Discussion includes the role of CBD relative to mood, sleep, energy, pain and daily performance. The innate CBD functions with the body and the significance and location of CBD receptors and what their presence teaches us as clinicians. Clinical cases are shared along with the potential role of HEMP derived bioactives as a whole plant extract as it relates to supporting healthful aging

    1.5 pharmacy CEUs approved by OBNM
  • This course requires an enrollment key
    Cost: US$ 55.00
    The CBD Evidence Base

    Presenter: Kevin Spelman, PhD
    Original Date: July 29, 2017

    Besides THC there are at least 60 other cannabinoids in the Cannabis plant. Besides the fascination with THC, there is a significant amount of attention being put on cannabidiol (CBD). Importantly, this cannabinoid does not induce euphoria but does show some intriguing activity in a number of molecular pathways, tissues and physiological systems. Beyond attenuating the euphoria of THC, anxiolytic, anti-inflammatory, analgesic, anti-seizure, anti-addictive and anti-neoplastic activities are prominent. In addition, it puts other receptors into play besides the CBRs. This presentation examines the evidence base for CBD, which is growing rapidly and offers broad spectrum and significant therapeutic potential.

    1.5 pharmacy CEUs approved by OBNM

  • Oregon Cannabis Law and Naturopathic Doctors

    Presenter: Vincent Sliwoski, JD
    Original Date: July 29, 2017

    This presentation covers the highly dynamic status of state and federal law as it relates to cannabis and naturopathic doctors as well as acupuncturists.

    “Marijuana” is a federally controlled substance, listed on Schedule I of the federal Controlled Substances Act (“CSA”). As of April, 2017, marijuana has been descheduled entirely from the Oregon State Controlled Substances Act (cf. SB 302 and 303). Still, given the status of federal law and Supreme Court jurisprudence on the topic, federal law enforcement authorities retain the right to enforce the federal CSA even in states where cannabis is legal, such as Oregon.

    The federal Drug Enforcement Agency (DEA) issues licenses to physicians to prescribe controlled substances. These licenses do not include the authorization to prescribe Schedule I drugs. Still, courts have held that doctors are protected by the First Amendment free speech rights, which includes the right to discuss (but not prescribe) particular health care options with patients, including cannabis.

    1.0 general CEUs approved by OBNM
  • Cannabis Chemistry: Understanding the Terpenes

    Presenter: Kevin Spelman, PhD
    Original Date: July 30, 2017

    While much of the medical community is learning about the cannabinoids, the Cannabis industry itself has been enamored by the terpenes, specifically the mono and sesquiterpenes, with good reason. Many of the terpenes are known to be psychotropic, alter pharmacokinetics and potentially enhance the pharmacodynamic of the cannabinoids. The current understanding of chemovars, is arguably about terpene profiles rather than cannabinoid profiles, and these profiles offer a better understanding of indica vs. sativa differences than supposed speciation.

    1.5 pharmacy CEUs approved by OBNM

  • Cannabinoids for Inflammation and the Immune System

    Presenter: Sunil Pai, MD
    Original Date: July 30, 2017

    Inflammation in now recognized as a triggering mechanism related to almost every disease including cancer. Unfortunately, conventional medical options that lower inflammation from prescription pharmaceuticals such as TNF-alpha blockers and other biologics to over-the-counter NSAIDs all have Black Box Warnings and severe side effects. These medications help lower inflammatory mechanisms and provide only symptomatic relief. Many increase the chronic progression of the disease and only suppress the immune function, which leads to lowering the healing response and cause further side effects. CBD (cannabidiols) provide a new approach for the treatment of chronic inflammatory diseases without the side effects and may improve physiological healing responses.

    For cancer, CBD is used not only for palliative effects, but also to decrease tumor growth by modulating key cell signaling pathways involved in the control of cancer cell proliferation and survival. In addition, cannabinoids inhibit angiogenesis and decrease metastasis in various tumor types. This lecture provides an understanding of cannabinoids as antitumor agents, focusing on their molecular mechanisms of action and opportunities for their use in combination therapy.

    1.5 pharmacy CEUs approved by OBNM
  • Cannabis in Cancer Care

    Presenter: Neil McKinney, ND
    Original Date: July 30, 2017

    Cannabis is an ancient medicine, marginalized due its prohibition as a “narcotic”. Cannabinoids are now being embraced widely as a cancer medicine, with little to no human evidence of safety or efficacy.

    This presentation clarifies the endocannabinoids we all possess, and how the cannabinoids from the cannabis plant interact with this innate regulatory system and its receptors. It outlines how medical marijuana is derived, and how it can be administered as edibles, by vaping, and as highly concentrated oil extracts by mouth or suppositories. The role of cannabis in symptom palliation will be explained, such as for nausea and in chemotherapy. The potential for tumour reduction, even cure, is also addressed, with case histories. The dark side of cannabis overdose, dependence, addiction, psychosis, tumour lysis syndrome and contraindications and drug interactions are also presented. Further resources in print, websites and published science are provided.

    1.5 pharmacy CEUs approved by OBNM

  • Cannabinoids and Opiates: Crosstalk and Connections with Regard to Reward, Addiction, Dependence and Recovery

    Presenter: Kevin Wilson, ND
    Original Date: July 30, 2017

    Given the opiate addiction crisis and the limited treatment options as well as the surge in cannabis legalization and use, this presentation explores the interactions of cannabinoids and opiates for pain relief, opiate withdrawal and addiction.

    Two case presentations elucidate how two different individuals used cannabis to eliminate opiate use and dependence.

    1.5 pharmacy CEUs approved by OBNM

Privacy Policy